Neuraxis, Inc.
NRXSNeuraxis, Inc. in brief
Neuraxis, Inc. is a listed company in the Medical Devices industry, based in Carmel, Indiana, USA. Its market value was $95 M on 13 October 2026, which makes it the 18,885th largest listed company in the world and the 3,534th largest in the USA on this site. In the year to December 2025 it had sales of $4 M and a net loss of $8 M. It employs about 24 people and Brian Carrico is its chief executive. By market, the largest shares of its 2025 sales came from CALIFORNIA (25%), OHIO (16%) and MASSACHUSETTS (7%). Its shares trade under the symbol NRXS (NYSE).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Neuraxis, Inc.
Neuraxis, Inc. is a first-to-market growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. With several indications in the market and additional clinical trials of Percutaneous Electrical Nerve Field Stimulation (PENFS) in multiple pediatric and adult conditions underway, we are focused on unmet GI healthcare needs in children and adults. We are dedicated to advancing science with our proprietary IB-Stim® therapy, based on our PENFS technology, which was developed internally by the Company. We believe that superior science and evidence-based research are necessary for adoption by the medical and scientific community. Additional clinical trials of PENFS in multiple pediatric and adult conditions are underway, focused on unmet healthcare needs in children and adults. See “Our Pipeline” for more information.
From the company's annual report filed with the US SEC: read the report
Neuraxis, Inc. timeline
- 2022
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2023
- 🔔Initial public offeringFinal prospectus filed with the SEC on 11 August 2023; shares registered for exchange trading on 8 August 2023.
- 2025
- 💰Record revenue of $4 millionFY2025, the highest of the 4 years on record.
Events of Neuraxis, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
Not enough history yet.
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 14.6×
- Price / book
- 28.1×
- Free cash flow yield
- -6.8%
- Net margin (TTM)
- -185.2%
- Operating margin
- -219.3%
- Return on equity
- -356.2%
- Liabilities / assets
- 46.9%
- Net debt
- $-0M
- Revenue growth
- +32.7%
- R&D / revenue
- 13.7%
- Revenue per employee
- $149 K
- Profit per employee
- $-325 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $4M | +32.7% | $-8M | $-8M | -218.5% |
| Dec 2024 | $3M | +9.3% | $-7M | $-8M | -306.3% |
| Dec 2023 | $2M | -8.2% | $-7M | $-15M | -594.7% |
| Dec 2022 | $3M | — | $-3M | $-5M | -178.4% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-6M | $0M | $-6M | $-0.95 | — |
| Dec 2024 | $-6M | $0M | $-6M | $-1.22 | — |
| Dec 2023 | $-7M | $0M | $-7M | $-4.50 | — |
| Dec 2022 | $-2M | $0M | $-2M | $-2.77 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $2M (+150.6% on a year earlier), net income $-7M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Oct 14, 20268-KCurrent reportOther events
- Aug 19, 20268-KCurrent reportDirectors or officers changed · Other events
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Jul 10, 20268-KCurrent reportOther events
- Jun 12, 20268-KCurrent reportShareholder vote
- May 12, 202610-QQuarterly report · period to Mar 2026
- Apr 28, 2026DEF 14AProxy statement
- Apr 22, 20268-KCurrent reportOther events
- Apr 21, 20268-KCurrent reportResults of operations
- Mar 19, 202610-KAnnual report · period to Dec 2025
- Nov 10, 202510-QQuarterly report · period to Sep 2025
Official filings of Neuraxis, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $4 M
- Operating income
- $-8 M
- Net income
- $-8 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $6 M
- Total liabilities
- $3 M
- Total equity
- $3 M
As of December-2025
Top 40 institutional investors in Neuraxis, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Rosalind Advisors, Inc. | 548,123 | +40,068 (+7.89%) | 3.86% | $4 M | Nov 16, 2026 |
| 2 | AIGH Capital Management LLC | 540,292 | +20,354 (+3.91%) | 3.81% | $4 M | Nov 2, 2026 |
| 3 | Vanguard Capital Management LLC | 341,952 | +6,159 (+1.83%) | 2.41% | $3 M | Nov 13, 2026 |
| 4 | Money Concepts Capital Corp | 235,674 | +7,645 (+3.35%) | 1.66% | $2 M | Nov 6, 2026 |
| 5 | Renaissance Technologies LLC | 156,300 | -13,100 (-7.73%) | 1.10% | $1 M | Nov 12, 2026 |
| 6 | Geode Capital Management, LLC | 90,999 | -5,362 (-5.56%) | 0.64% | $1 M | Nov 6, 2026 |
| 7 | Parsons Capital Management Inc/ri | 90,807 | -27,001 (-22.92%) | 0.64% | $1 M | Oct 28, 2026 |
| 8 | Eddie Patel Inc | 79,542 | +19,778 (+33.09%) | 0.56% | $1 M | Nov 2, 2026 |
| 9 | BlackRock, Inc. | 60,125 | +1,473 (+2.51%) | 0.42% | $0 M | Nov 13, 2026 |
| 10 | Vanguard Fiduciary Trust Co | 50,996 | -8,696 (-14.57%) | 0.36% | $0 M | Nov 13, 2026 |
| 11 | State Street Corp | 47,737 | +3,500 (+7.91%) | 0.34% | $0 M | Nov 12, 2026 |
| 12 | Centiva Capital, LP | 36,960 | -566 (-1.51%) | 0.26% | $0 M | Nov 13, 2026 |
| 13 | T3 Companies, LLC | 27,200 | New | 0.19% | $0 M | Oct 22, 2026 |
| 14 | Northern Trust Corp | 23,083 | 0 (0.00%) | 0.16% | $0 M | Nov 16, 2026 |
| 15 | Susquehanna International Group, LLP | 21,775 | New | 0.15% | $0 M | Nov 16, 2026 |
| 16 | Elevation Point Wealth Partners, LLC | 21,000 | +6,700 (+46.85%) | 0.15% | $0 M | Nov 5, 2026 |
| 17 | Prelude Capital Management, LLC | 19,107 | New | 0.13% | $0 M | Nov 16, 2026 |
| 18 | Citadel Advisors LLC | 18,363 | -66,690 (-78.41%) | 0.13% | $0 M | Nov 16, 2026 |
| 19 | Bridgeway Capital Management, LLC | 16,724 | -276 (-1.62%) | 0.12% | $0 M | Nov 16, 2026 |
| 20 | Empowered Funds, LLC | 16,724 | New | 0.12% | $0 M | Nov 13, 2026 |
| 21 | Marshall Wace, LLP | 16,383 | -112,372 (-87.28%) | 0.12% | $0 M | Nov 13, 2026 |
| 22 | Vestmark Advisory Solutions, Inc. | 16,000 | +1,700 (+11.89%) | 0.11% | $0 M | Nov 16, 2026 |
| 23 | UBS Group AG | 15,430 | -20,145 (-56.63%) | 0.11% | $0 M | Nov 10, 2026 |
| 24 | Wealthcare Advisory Partners LLC | 15,188 | 0 (0.00%) | 0.11% | $0 M | Oct 21, 2026 |
| 25 | HRT Financial LP | 14,188 | -134 (-0.94%) | 0.10% | $0 M | Nov 13, 2026 |
Show all 40: investors 26 to 40
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Occudo Quantitative Strategies LP | 12,765 | -1,409 (-9.94%) | 0.09% | $0 M | Nov 16, 2026 |
| 27 | Jane Street Group, LLC | 11,864 | New | 0.08% | $0 M | Nov 12, 2026 |
| 28 | LPL Financial LLC | 10,000 | 0 (0.00%) | 0.07% | $0 M | Nov 6, 2026 |
| 29 | Morgan Stanley | 5,802 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 30 | Vanguard Global Advisers, LLC | 5,226 | New | 0.04% | $0 M | Nov 13, 2026 |
| 31 | Ascentis Independent Advisors | 1,990 | New | 0.01% | $0 M | Nov 3, 2026 |
| 32 | Jones Financial Companies Lllp | 1,176 | New | 0.01% | $0 M | Nov 13, 2026 |
| 33 | Tower Research Capital LLC (TRC) | 1,111 | -48 (-4.14%) | 0.01% | $0 M | Nov 16, 2026 |
| 34 | Ulland Investment Advisors, LLC | 1,000 | 0 (0.00%) | 0.01% | $0 M | Oct 13, 2026 |
| 35 | Royal Bank Of Canada | 345 | -155 (-31.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 36 | Simplex Trading, LLC | 255 | New | 0.00% | $0 M | Nov 4, 2026 |
| 37 | Steward Partners Investment Advisory, LLC | 150 | New | 0.00% | $0 M | Nov 13, 2026 |
| 38 | Caitong International Asset Management Co., Ltd | 54 | +40 (+285.71%) | 0.00% | $0 M | Oct 29, 2026 |
| 39 | FMR LLC | 10 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 40 | Barclays PLC | 3 | -401 (-99.26%) | 0.00% | $0 M | Nov 6, 2026 |
Mutual funds holding Neuraxis, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 222,869 | $2 M | 1.6% | <0.01% | +77% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 99,792 | $1 M | 0.70% | <0.01% | −0.3% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 43,388 | $0 M | 0.31% | <0.01% | +2.2% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 29,351 | $0 M | 0.21% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 17,000 | $0 M | 0.12% | 0.08% | +240% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 13,872 | $0 M | 0.10% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 12,505 | $0 M | 0.09% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 7,463 | $0 M | 0.05% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 4,169 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 1,947 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 282 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 11 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Neuraxis, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Thomas Joeseph CarricoCRO, CCO, CPO | Buy | +328 | $4.840 | $2 K | 199,673 | Form 4 |
| filed | Brian Allen CarricoChief Executive Officer, Director | Buy | +268 | $4.840 | $1 K | 227,604 | Form 4 |
| filed | Timothy Robert HenrichsChief Financial Officer | Buy | +1,937 | $4.840 | $9 K | 9,530 | Form 4 |
| filed | Adrian MirandaCMO, SVP Science & Tech | Grant or award | +199,106 | — | — | 199,106 | Form 4 |
| filed | Brian Allen CarricoChief Executive Officer, Director | Grant or award | +199,188 | — | — | 227,336 | Form 4 |
| filed | Thomas Joeseph CarricoCRO, CCO, CPO | Grant or award | +193,678 | — | — | 199,345 | Form 4 |
| filed | Kristin A. FergeDirector | Grant or award | +31,134 | $6.280 | $196 K | 67,072 | Form 4 |
| filed | Jane Elizabeth KeyserDirector | Grant or award | +26,073 | $6.280 | $164 K | 72,408 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Neuraxis, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q1 2023 | Q1 2024 | $0.1M |
Fails to deliver
- : 5,548 shares at $6.72
- : 435 shares at $7.40
- : 685 shares at $5.70
- : 33 shares at $5.75
- : 279 shares at $5.74
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Neuraxis, Inc. scorecard#
Passes 4 of the 18 checks that could be worked out: strongest in growth (2 of 4), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 13, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median28.1×Price to book 28.1× against Medical Devices's median of 2.5×.
- ✗Price to sales below its peers' median14.6×Price to sales 14.6× against Medical Devices's median of 2.4×.
- ✗Free cash flow yield above 5%-6.8%Free cash flow is -6.8% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth2 of 4
- ✓Revenue grew in the newest year32.7%Revenue up 32.7% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years10.0%10.0% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median10.0%10.0% a year against Medical Devices's median of 10.8% (73 companies).
- ✗Earnings per share grew in the newest year-0.95 vs -1.22Diluted EPS -0.95 in fiscal 2025 against -1.22 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 4
- ✗Profitable in the newest year-$8 MNet income -$8 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- ✗Operating margin above its peers' median-219.3%-219.3% against Medical Devices's median of -8.2% (86 companies).
- ✗Return on equity above 15%-285.2%-285.2% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-219.3%-219.3% in fiscal 2025 against -125.7% in 2022.
Financial health2 of 4
- ✓Short-term assets cover short-term liabilities2.0×Current ratio 2.05 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-111.9×Operating income -111.9 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone2.02Z-score 2.02 (grey zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year31.3%Diluted shares up 31.3% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Neuraxis, Inc.'s statements, beside the median of Medical Devices.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -219.3% | -8.2% | |
| Net margin | -218.5% | -10.4% | |
| Return on equity | -285.2% | -16.8% | |
| Revenue growth, 3 years a year | 10.0% | 10.8% | |
| Revenue growth | 32.7% | 10.4% | |
| Free cash flow margin | -181.0% | -1.9% |
3of 8on the Piotroski tests of financial strength
- Net loss of $8 million, the 4th loss-making year in a row.
- Free cash flow was negative: -$6 million.
- The share count rose 31.3% in the year.
- Operating income covers the interest bill only -111.9 times.
Neuraxis, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 3,569+32.9%100% | 2,686+9.2%100% | 2,460−8.4%100% | 2,685—100% | |
| Cost of revenue | 563+55.5%15.8% | 362+19.3%13.5% | 303+2.1%12.3% | 297—11.1% | |
| Gross profit | 3,006+29.4%84.2% | 2,324+7.8%86.5% | 2,157−9.7%87.7% | 2,388—88.9% | |
| Research and development | 494+13.8%13.8% | 434r206+156%16.1% | 169−25.0%6.9% | 226—8.4% | |
| Selling and marketing | 2,280+55.2%63.9% | 1,469r325+354%54.7% | 324−21.3%13.2% | 411—15.3% | |
| General and administrative | 8,063+6.4%226% | 7,578r8,950−9.0%282% | 8,328+62.6%339% | 5,123—191% | |
| Operating income | −7,830—−219% | −7,157—−266% | −6,664—−271% | −3,372—−126% | |
| Interest expense and finance costs | 74−57.6%2.1% | 174−63.4%6.5% | 476+49.5%19.4% | 319—11.9% | |
| Other non-operating income (expense) | 29—0.8% | −1,085—−40.4% | −7,962—−324% | −1,408—−52.4% | |
| Net income attributable to shareholders | −7,801—−219% | −8,242—−307% | −14,627—−595% | −4,780—−178% | |
| Earnings per share, basic | -0.95—— | -1.22—— | -4.50—— | -2.77—— | |
| Earnings per share, diluted | -0.95—— | -1.22—— | -4.50—— | -2.77—— | |
| Shares, weighted average (basic) | 9.1+31.3%— | 6.9+113%— | 3.3+62.3%— | 2.0—— | |
| Shares, weighted average (diluted) | 9.1+31.3%— | 6.9+113%— | 3.3+62.3%— | 2.0—— | |
| Balance sheet | |||||
| Cash and cash equivalents | 4,965+34.3%77.5% | 3,697+4606%77.7% | 79−69.0%15.4% | 254—17.1% | |
| Receivables | 196−20.0%3.1% | 245+234%5.1% | 73−58.0%14.4% | 174—11.8% | |
| Inventory | 257+480%4.0% | 44+109%0.9% | 21−55.9%4.2% | 48—3.3% | |
| Other current assets | 315+12.5%4.9% | 280+302%5.9% | 70+9495%13.7% | 0.7—0.0% | |
| Current assets | 5,733+34.4%89.5% | 4,266+1658%89.7% | 243−49.1%47.6% | 477—32.2% | |
| Property, plant and equipment | 76−16.0%1.2% | 90+1.6%1.9% | 89+0.6%17.4% | 88—5.9% | |
| Right-of-use (leased) assets | 262−8.1%4.1% | 285+305%6.0% | 70−30.7%13.8% | 101—6.8% | |
| Other intangible assets | 275+184%4.3% | 97−10.6%2.0% | 108+39.3%21.2% | 78—5.2% | |
| Total assets | 6,404+34.6%100% | 4,758+834%100% | 509−65.6%100% | 1,481—100% | |
| Accounts payable | 139−76.7%2.2% | 597−50.4%12.5% | 1,204−24.4%236% | 1,592—108% | |
| Customer deposits | 29−11.9%0.4% | 33−56.6%0.7% | 75+26.7%14.7% | 59—4.0% | |
| Current liabilities | 2,792+14.7%43.6% | 2,433+29.0%51.1% | 1,886−73.0%370% | 6,978—471% | |
| Lease liabilities (non-current) | 203−21.0%3.2% | 256+848%5.4% | 27−64.5%5.3% | 76—5.1% | |
| Non-current liabilities | 213−17.1%3.3% | 256+848%5.4% | 27−64.5%5.3% | 76—5.1% | |
| Total liabilities | 3,005+11.7%46.9% | 2,690+40.6%56.5% | 1,913−72.9%375% | 7,054—476% | |
| Retained earnings | −64,600—−1009% | −56,800—−1194% | −48,558—−9531% | −33,931—−2292% | |
| Shareholders' equity | 3,399+64.4%53.1% | 2,068—43.5% | −1,403—−275% | −5,574—−376% | |
| Total liabilities and equity | 6,404+34.6%100% | 4,758+834%100% | 509−65.6%100% | 1,481—100% | |
| Shares outstanding | 11+52.4%— | 7.0+7.4%— | 6.5+232%— | 2.0—— | |
| Cash-flow statement | |||||
| Depreciation and amortization | 60+57.3%1.7% | 38−7.1%1.4% | 41+9.7%1.7% | 37—1.4% | |
| Share-based compensation | 597+163%16.7% | 227—8.5% | 0−100%0.0% | 27—1.0% | |
| Cash from operating activities | −6,433—−180% | −6,098—−227% | −6,694—−272% | −2,298—−85.6% | |
| Capital expenditure | −31—−0.9% | −28—−1.0% | −31—−1.3% | −1.4—−0.1% | |
| Intangible assets bought | −100—−2.8% | — | −41—−1.7% | −60—−2.2% | |
| Cash from investing activities | −131—−3.7% | −28—−1.0% | −72—−2.9% | −61—−2.3% | |
| Shares issued | 7,728—217% | — | 4,847—197% | — | |
| Cash from financing activities | 7,832−19.6%219% | 9,744+47.9%363% | 6,591+188%268% | 2,292—85.4% | |
| Change in cash | 1,268−65.0%35.5% | 3,618—135% | −175—−7.1% | −67—−2.5% | |
| Report | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Q3 FY2026to Sep 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||
| Revenue | 2,028+150%100% | 1,608+79.5%100% | 968*+27.2%100% | 811+21.7%100% | 894+46.2%100% | 896+38.5%100% | 761*+43.2%100% | 667+39.6%100% | 612—100% | 647—100% | 531*—100% | 477—100% | |
| Cost of revenue | 272+101%13.4% | 218+56.6%13.6% | 142*+34.8%14.6% | 135+39.6%16.7% | 147+99.6%16.4% | 139+85.8%15.6% | 105*+45.2%13.8% | 97+44.2%14.6% | 73—12.0% | 75—11.6% | 72*—13.6% | 67—14.1% | |
| Gross profit | 1,756+160%86.6% | 1,390+83.8%86.4% | 826*+26.0%85.4% | 676+18.7%83.3% | 747+38.9%83.6% | 756+32.3%84.4% | 656*+42.9%86.2% | 570+38.9%85.4% | 538—88.0% | 572—88.4% | 459*—86.4% | 410—85.9% | |
| Research and development | 289+121%14.2% | 100−15.5%6.2% | 146*+5.6%15.1% | 131+3.6%16.1% | 115r58+112%12.9% | 118r61+2016%13.2% | 138r74*—18.2% | 126r72+181%18.9% | 54—8.9% | 5.6—0.9% | — | 45—9.4% | |
| Selling and marketing | 1,001+31.3%49.4% | 824+64.8%51.3% | 586*+28.4%60.5% | 763+125%94.0% | 534r142+758%59.7% | 500r134+525%55.8% | 456r98*+528%59.9% | 339r95+427%50.8% | 62—10.2% | 80—12.4% | 73*—13.7% | 64—13.4% | |
| General and administrative | 7,045+274%347% | 2,206−9.3%137% | 1,812*+18.5%187% | 1,883+7.2%232% | 1,816r2,265−30.9%203% | 2,433r2,857+5.0%272% | 1,528r1,951*−24.0%201% | 1,756r2,053−47.2%263% | 2,628—430% | 2,318—358% | 2,012*—379% | 3,323—696% | |
| Operating income | −6,579—−324% | −1,741—−108% | −1,717*—−177% | −2,100—−259% | −1,718—−192% | −2,295—−256% | −1,467*—−193% | −1,651—−248% | −2,207—−361% | −1,832—−283% | −1,623*—−305% | −3,022—−633% | |
| Interest expense and finance costs | 20−32.1%1.0% | 26+1071%1.6% | 29*+1096%3.0% | 30−54.1%3.7% | 13−83.4%1.5% | 2.2−91.6%0.2% | 2.4*−89.4%0.3% | 65−37.0%9.7% | 81—13.2% | 27—4.1% | 23*—4.2% | 103—21.5% | |
| Other non-operating income (expense) | 33—1.7% | −21−226%−1.3% | 8.2*−56.1%0.8% | −23—−2.8% | 27—3.1% | 16—1.8% | 19*−39.5%2.5% | −104—−15.6% | −711—−116% | −289—−44.6% | 31*—5.8% | −5,603r−1,882—−1174% | |
| Net income including minority interests | −6,545—−323% | — | — | −2,123—−262% | −1,690—−189% | — | — | — | — | — | — | — | |
| Net income attributable to shareholders | −6,545—−323% | −1,761—−110% | −1,709*—−176% | −2,123—−262% | −1,690—−189% | −2,279—−254% | −1,448*—−190% | −1,755—−263% | −2,918—−477% | −2,121—−328% | −1,592*—−300% | −8,625r−4,904—−1807% | |
| Earnings per share, basic | -0.52—— | -0.18—— | — | -0.24—— | -0.22—— | -0.33—— | — | -0.25—— | -0.42—— | -0.32—— | — | -2.38r-1.35—— | |
| Earnings per share, diluted | -0.52—— | -0.18—— | — | -0.24—— | -0.22—— | -0.33—— | — | -0.25—— | -0.42—— | -0.32—— | — | -2.38r-1.35—— | |
| Shares, weighted average (basic) | 13+31.5%— | 11+46.7%— | — | 9.9+37.7%— | 8.5+23.1%— | 7.5+13.9%— | — | 7.2+97.8%— | 6.9—— | 6.6—— | — | 3.6—— | |
| Shares, weighted average (diluted) | 13+31.5%— | 11+46.7%— | — | 9.9+37.7%— | 8.5+23.1%— | 7.5+13.9%— | — | 7.2+97.8%— | 6.9—— | 6.6—— | — | 3.6—— | |
| Balance sheet | |||||||||||||
| Cash and cash equivalents | 4,477+2.3%67.3% | 7,079+253%80.9% | 4,965+34.3%77.5% | 4,377+1578%75.8% | 5,988+239%84.5% | 2,005+2353%66.2% | 3,697+4606%77.7% | 261−65.7%22.8% | 1,765—67.0% | 82—8.6% | 79—15.4% | 761—61.6% | |
| Receivables | 809+646%12.2% | 385+58.0%4.4% | 196−20.0%3.1% | 109+106%1.9% | 129−12.7%1.8% | 244+169%8.0% | 245+234%5.1% | 53−60.3%4.6% | 147—5.6% | 91—9.6% | 73—14.4% | 132—10.7% | |
| Inventory | 255+131%3.8% | 238+537%2.7% | 257+480%4.0% | 110+391%1.9% | 131+208%1.9% | 37+85.3%1.2% | 44+109%0.9% | 22−35.0%2.0% | 43—1.6% | 20—2.1% | 21—4.2% | 35—2.8% | |
| Other current assets | 512+30.6%7.7% | 441+73.3%5.0% | 315+12.5%4.9% | 392+32.4%6.8% | 370+137%5.2% | 255+18.2%8.4% | 280+302%5.9% | 296+665%25.9% | 156—5.9% | 215—22.8% | 70—13.7% | 39—3.1% | |
| Current assets | 6,053+21.3%90.9% | 8,143+220%93.1% | 5,733+34.4%89.5% | 4,988+689%86.3% | 6,619+213%93.4% | 2,541+523%83.9% | 4,266+1658%89.7% | 632−34.6%55.3% | 2,112—80.2% | 408—43.1% | 243—47.6% | 967—78.2% | |
| Property, plant and equipment | 57−33.4%0.9% | 68−34.9%0.8% | 76−16.0%1.2% | 85−9.3%1.5% | 101+5.9%1.4% | 104+9.0%3.4% | 90+1.6%1.9% | 94+17.3%8.2% | 95—3.6% | 95—10.1% | 89—17.4% | 80—6.5% | |
| Right-of-use (leased) assets | 211−23.8%3.2% | 245−9.4%2.8% | 262−8.1%4.1% | 277−6.9%4.8% | 257−20.7%3.6% | 271−19.7%8.9% | 285+305%6.0% | 298+282%26.1% | 323—12.3% | 337—35.7% | 70—13.8% | 78—6.3% | |
| Other intangible assets | 264−6.8%4.0% | 266+184%3.0% | 275+184%4.3% | 283+185%4.9% | 91−11.2%1.3% | 94−10.9%3.1% | 97−10.6%2.0% | 99−10.4%8.7% | 103—3.9% | 105—11.2% | 108—21.2% | 111—9.0% | |
| Total assets | 6,655+15.2%100% | 8,746+189%100% | 6,404+34.6%100% | 5,776+405%100% | 7,088+169%100% | 3,030+220%100% | 4,758+834%100% | 1,143−7.5%100% | 2,633—100% | 946—100% | 509—100% | 1,236—100% | |
| Accounts payable | 397−55.2%6.0% | 305−42.9%3.5% | 139−76.7%2.2% | 886−7.9%15.3% | 465−58.5%6.6% | 535−56.8%17.7% | 597−50.4%12.5% | 962+69.8%84.2% | 1,118—42.5% | 1,237—131% | 1,204—236% | 567—45.8% | |
| Customer deposits | — | 30−21.5%0.3% | 29−11.9%0.4% | 37−56.0%0.6% | 32−61.1%0.5% | 38−56.1%1.2% | 33−56.6%0.7% | 85+22.5%7.4% | 82—3.1% | 86—9.1% | 75—14.7% | 69—5.6% | |
| Current liabilities | 2,888−8.2%43.4% | 2,814+33.9%32.2% | 2,792+14.7%43.6% | 3,147+18.1%54.5% | 2,347−69.1%33.1% | 2,101−44.9%69.4% | 2,433+29.0%51.1% | 2,664+18.0%233% | 7,594—288% | 3,816—403% | 1,886—370% | 2,258—183% | |
| Lease liabilities (non-current) | 145−34.2%2.2% | 184−22.9%2.1% | 203−21.0%3.2% | 220−19.5%3.8% | 220−26.2%3.1% | 239−24.1%7.9% | 256+848%5.4% | 273+594%23.9% | 298—11.3% | 314—33.3% | 27—5.3% | 39—3.2% | |
| Non-current liabilities | — | — | 213−17.1%3.3% | 344+26.1%6.0% | 487+63.6%6.9% | 670+113%22.1% | 256+848%5.4% | 273+594%23.9% | 298—11.3% | 314—33.3% | 27—5.3% | 39—3.2% | |
| Total liabilities | 3,033−13.1%45.6% | 2,998+8.2%34.3% | 3,005+11.7%46.9% | 3,491+18.9%60.4% | 2,835−64.1%40.0% | 2,771−32.9%91.5% | 2,690+40.6%56.5% | 2,937+27.9%257% | 7,892—300% | 4,130—437% | 1,913—375% | 2,297—186% | |
| Retained earnings | −76,400—−1148% | −66,362—−759% | −64,600—−1009% | −62,892—−1089% | −60,769—−857% | −59,078—−1950% | −56,800—−1194% | −55,352—−4842% | −53,596—−2035% | −50,679—−5359% | −48,558—−9531% | −46,966r−43,245—−3800% | |
| Shareholders' equity | 3,622+58.5%54.4% | 5,748+2124%65.7% | 3,399+64.4%53.1% | 2,285—39.6% | 4,253—60.0% | 258—8.5% | 2,068—43.5% | −1,794—−157% | −5,258—−200% | −3,184—−337% | −1,403—−275% | −1,061—−85.9% | |
| Total liabilities and equity | 6,655+15.2%100% | 8,746+189%100% | 6,404+34.6%100% | 5,776+405%100% | 7,088+169%100% | 3,030+220%100% | 4,758+834%100% | 1,143−7.5%100% | 2,633—100% | 946—100% | 509—100% | 1,236—100% | |
| Shares outstanding | 14+39.7%— | 11+58.7%— | 11+52.4%— | 9.9+41.6%— | 9.9+44.1%— | 7.2+9.4%— | 7.0+7.4%— | 7.0+35.6%— | 6.8—— | 6.6—— | 6.5—— | 5.1—— | |
| Cash-flow statement | |||||||||||||
| Depreciation and amortization | 17+3.8%0.8% | 16+157%1.0% | 24*+251%2.5% | 16+74.8%2.0% | 13+17.5%1.4% | 6.4−40.8%0.7% | 6.9*−34.3%0.9% | 9.3−9.4%1.4% | 11—1.8% | 11—1.7% | 10*—2.0% | 10*—2.1% | |
| Share-based compensation | — | 329+211%20.5% | 157*—16.2% | 0—0.0% | 0—0.0% | 106−53.4%11.8% | 0*—0.0% | 0—0.0% | 0*—0.0% | 227—35.1% | — | — | |
| Cash from operating activities | — | −1,230—−76.5% | −1,934*—−200% | −1,428*—−176% | −1,467*—−164% | −1,604—−179% | −1,758*—−231% | −1,393*—−209% | −1,615*—−264% | −1,332—−206% | −2,630*—−495% | −2,816*—−590% | |
| Capital expenditure | — | — | −5.9*—−0.6% | 0*—0.0% | −7.3*—−0.8% | −18—−2.0% | 0*—0.0% | −4.4*—−0.7% | −8.7*—−1.4% | −15—−2.3% | −16*—−3.0% | −2.7*—−0.6% | |
| Intangible assets bought | — | — | −50*—−5.2% | — | — | — | — | — | — | — | 0*—0.0% | −40*—−8.4% | |
| Cash from investing activities | — | — | −106*—−10.9% | 0—0.0% | −7.3—−0.8% | −18—−2.0% | 0*—0.0% | −4.4—−0.7% | −8.7—−1.4% | −15—−2.3% | −16*—−3.0% | −43*—−8.9% | |
| Shares issued | — | 2,990—186% | 2,728*—282% | 0*—0.0% | — | — | — | — | — | — | −617*—−116% | — | |
| Cash from financing activities | — | 3,343—208% | 2,628*−49.4%271% | −184*—−22.7% | 5,458*+65.0%610% | −70−105%−7.8% | 5,194*+165%682% | −107*−103%−16.1% | 3,307*—541% | 1,350—209% | 1,963*—369% | 3,569*—747% | |
| Change in cash | — | 2,114—131% | 588*−82.9%60.7% | −1,611*—−199% | 3,983*+137%445% | −1,692−53092%−189% | 3,436*—451% | −1,504*−312%−226% | 1,684*—275% | 3.2—0.5% | −683*—−128% | 710*—149% | |
| Report | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Neuraxis, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Countries and regions
- All other States$1 M35%+62%
- CALIFORNIA$1 M25%+15%
- OHIO$1 M16%+35%
- MASSACHUSETTS$0 M7.4%+80%
- ILLINOIS$0 M6.2%-12%
- WISCONSIN$0 M6.0%+38%
- FLORIDA$0 M4.0%-6.7%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Neuraxis, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Brian Carrico | $936 K | $1.3 M | $652 K | $72 |
| 2024Brian Carrico | $578 K | $578 K | $460 K | $37 |
| 2023Brian Carrico | $839 K | $839 K | $367 K | $42 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Neuraxis, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 4 · Material agreement 7 · Agreement ended 1 · New debt 2 · Unregistered share sale 3 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 5
| Filed | What happened | Filing |
|---|---|---|
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officersMaterial agreementAgreement ended | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Material agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Unregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreementNew debt | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Aug 19, 2026
H-1B hiring at Neuraxis, Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $72 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Staff AccountantAccountants and Auditors | 1 | $72 K |
Where: Carmel, IN 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as NeurAxis, Inc.
How Neuraxis, Inc. compares in Medical Devices
- Market cap$95 M · higher than 35% of 142
- Revenue$4 M · higher than 12% of 155
- Net margin-185.2% · higher than 8% of 144
- Revenue growth32.7% · higher than 85% of 104
- Price / sales14.6× · lower than 5% of 96
- Price / book28.1× · lower than 3% of 99
- FCF yield-6.8% · higher than 35% of 76
Peer comparison · Medical Devices
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Neuraxis, Inc.🇺🇸 | $95 M | — | -185.2% | +32.7% |
| Abbott Laboratories🇺🇸 | $181.1 B | 38.5× | 9.8% | +5.7% |
| Medtronic plc🇺🇸 | $121.2 B | 23.2× | 13.9% | +8.4% |
| Stryker Corporation🇺🇸 | $116.5 B | 32.2× | 13.8% | +11.2% |
| Boston Scientific Corporation🇺🇸 | $66.2 B | 18.9× | 16.6% | +19.9% |
| Edwards Lifesciences Corporation🇺🇸 | $52.8 B | 51.7× | 15.3% | +11.6% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳 | $27.8 B | 23.6× | 24.4% | — |
| STERIS plc🇮🇪 | $20.4 B | 24.6× | 13.4% | +8.7% |
| Zimmer Biomet Holdings, Inc.🇺🇸 | $18.2 B | 23.8× | 8.9% | +7.2% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 13, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Neuraxis, Inc.? Verify and update this profile — free
Show Neuraxis, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.